Drugs / hGM-CSF
hGM-CSF
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03338777 | Feb 2020 | melanoma | Hospital Italiano de Buenos Aires | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07218692 | Aug 2026 → Aug 2027 | clear cell renal carcinoma, sarcomatoid renal cell carcinoma | City of Hope Medical Center | Withdrawn | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT01232712 Background | Sep 2010 → May 2013 | plasma cell myeloma | Vaxil Therapeutics Ltd. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hGM-CSF | “Lipoplexes carrying hIL-2 and hGM-CSF genes (0.5 mg each)” NCT03338777 ↗ |
| Known as | rhGMCSF | “rhGMCSF (recombinant human granulocyte-monocyte colony stimulating factor)” NCT01232712 ↗ |
| Known as | Sturlimogene Erparepvec | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07218692 ↗ |
| Modality | Protein / enzyme biologic | “rhGMCSF (recombinant human granulocyte-monocyte colony stimulating factor)” NCT01232712 ↗ |
| Route | Subcutaneous | “subcutaneous vaccine produced with” NCT03338777 ↗ |